Skip to content
2000
Volume 24, Issue 4
  • ISSN: 1566-5240
  • E-ISSN: 1875-5666

Abstract

The coronavirus disease 2019 (Covid-19) pandemic has been considered a major threat to human health. Effective therapeutic approaches are urgently required. Spike protein and the Angiotensin-converting enzyme 2 (ACE2) receptors have critical roles in SARS-CoV-2 infection. As a result, these two proteins are considered potential targets for the development of a wide variety of biotherapeutics and vaccines for controlling Covid-19. The fusion proteins have desirable medicinal properties, including high serum half-life, stability, and solubility in the body. Moreover, other Fc-fusion proteins used to treat other diseases have no known side effects. These Fc-fusion proteins are valuable biopharmaceuticals and have been proposed as therapeutic candidates for the treatment and prevention of Covid-19 owing to their potential therapeutic benefits.

Loading

Article metrics loading...

/content/journals/cmm/10.2174/1566524023666230410093243
2024-04-01
2025-07-13
Loading full text...

Full text loading...

/content/journals/cmm/10.2174/1566524023666230410093243
Loading

  • Article Type:
    Review Article
Keyword(s): ACE2; Covid-19; Fc-fusion proteins; receptor; SARS-CoV-2; Spike protein
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test